Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.58 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7555668 | 0.90 | DPP4 (0.73) | DPP4KCNA5KCNH2PRKCAGSK3B | |
| SCHEMBL5238950 | 0.90 | DPP4 (0.57) | DPP4KCNA5KCNH2PRKCAGSK3B | |
| Hydrochloric Acid SCHEMBL5238032 | 0.89 | DPP4 (0.71) | DPP4KCNA5KCNH2PRKCAGSK3B | |
| SCHEMBL5238796 | 0.87 | DPP4 (0.58) | DPP4KCNA5KCNH2 | |
| SCHEMBL5235258 | 0.84 | DPP4 (0.53) | DPP4KCNA5KCNH2PRKCAGSK3B | |
| SCHEMBL5232687 | 0.84 | DPP4 (0.53) | DPP4KCNA5KCNH2PRKCAGSK3B | |
| SCHEMBL5239049 | 0.81 | GRIA2 (0.48) | DPP4KCNA5KCNH2PRKCAGSK3B | |
| SCHEMBL5238725 | 0.80 | DPP4 (0.56) | DPP4MAPT | |
| SCHEMBL5236714 | 0.79 | DPP4 (0.70) | DPP4KCNA5KCNH2 | |
| SCHEMBL5231074 | 0.79 | MAPK8 (0.46) | DPP4KCNA5KCNH2PRKCAGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | DPP4 2/4885KCNA5 1288/4885KCNH2 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.